ALIPAY
12.7.2021 04:10:06 CEST | Business Wire | Press release
Portuguese football star Cristiano Ronaldo today became the winner of the Gold Trophy of the Alipay Top Scorer Awards at UEFA EURO 2020. Regarded as one of the greatest footballers of all time, Ronaldo netted five goals and made one assist at the competition. Patrik Schick from the Czech Republic was awarded the Silver Trophy, scoring five goals, while France’s Karim Benzema was the recipient of the Bronze Trophy, netting four goals.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210711005035/en/
The Alipay Top Scorer trophies are the first major international football Top-Scorer trophies to embed blockchain in their design, incorporating a hash code at the base through which scoring records of the tournament’s top three scorers can be uploaded and permanently stored on a blockchain powered by AntChain. Using the hash code provided, Alipay will upload the trophy data to the blockchain, ensuring a permanent, immutable record of the top scorers’ achievements.
“Our warmest congratulations to Cristiano Ronaldo for his phenomenal performances at UEFA EURO 2020, and for winning the Alipay Top Scorer Gold Award,” said Eric Jing, Chairman and CEO of Ant Group, who presented the top scorer trophies via video from Hangzhou immediately after the final game of UEFA EURO 2020. “Just as we have used blockchain technology to permanently preserve the wonderful scoring moments of the top scorers like him, we will also keep working with UEFA, to explore innovative digital solutions that improve fans’ experiences while enjoying football.”
UEFA and AntChain, one of the technology brands of Ant Group, on June 10 announced a five-year global partnership to jointly explore using blockchain technology to accelerate the digital transformation of the football industry and improve the experiences of fans across the globe. Under the agreement, AntChain became the official global blockchain partner of UEFA EURO 2020.
To honor the performances of the top scoring players, an AntChain-developed digital record of highlights from the UEFA EURO 2020 top scorers will be preserved at UEFA’s headquarters, making it the first digital collectible in the history of the EURO Top Scorer.
“The top scoring moments digital collectible will serve as a lasting memento, encouraging football fans around the world to spread the team spirit and happiness that are part and parcel of this beloved sport,” said Mr. Jing.
The UEFA EURO 2020 Top Scorer trophies are designed by Alipay, the world’s leading digital payment and lifestyle platform operated by Ant Group, which has been UEFA’s global partner since November 2018.
On June 12, UEFA launched a new mini program with Alipay to improve engagement with mobile-savvy Chinese football fans. Dubbed the UEFA EURO 2020 Official Digital Hub, the mini program offers football fans across China an inside look at the tournament through regular news updates, interviews with key players, and much more. The UEFA mini program has rapidly become the most popular sports-focused mini program on Alipay, attracting over 12 million users as of July 11.
During the tournament, Alipay launched a campaign via the UEFA EURO 2020 Dream Tour mini program that enables authenticated users to earn points by engaging in various fan activities. Powered by AntChain's technologies, the top 1,600 users will receive gold, silver, and bronze digital trophies as a form of digital souvenir with certificates on a blockchain.
Alipay also launched "Top Scorers on Campus,” a new advocacy program dedicated to supporting the development of campus football in China. To inspire more teenagers to pursue their football dreams, the program will award trophies with the same design as the Alipay Top Scorer Gold Trophy of the UEFA EURO 2020 to the best young players in campus football tournaments across China. Similar to the UEFA EURO 2020 Top Scorer Trophy, these students’ scoring records and achievements will also be stored on a blockchain provided by AntChain.
About AntChain
AntChain is one of Ant Group’s technology brands. According to IPR Daily and patent database IncoPat, Ant Group held the highest number of published blockchain-related patent applications between 2017 and the six months ended June 30, 2020. Since the launch of Ant Group’s blockchain business in 2016, the company has pioneered the use of AntChain in over 50 blockchain commercial applications and use cases, including supply chain finance, cross-border remittance, charitable donations, and product provenance.
About Alipay
Alipay is the leading digital payment platform in China, serving hundreds of millions of users, and connecting them with merchants and partner financial institutions that offer inclusive financial services and digital daily life services such as food delivery, transport, entertainment, and healthcare.
Ant Group has further introduced Alipay+, the global cross-border mobile payments and marketing solution which enables merchants, especially small and medium-sized businesses, to better serve consumers from all over the world by collaborating with global partners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210711005035/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Azafaros to Present at BIO International Convention 202615.6.2026 07:00:00 CEST | Press release
Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A
Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 06:05:00 CEST | Press release
Autonomous launch, recovery, and recharge from military vehicles and fixed installations; Three-drone rotation provides persistent surveillance and real-time targeting data in contested environments Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integrati
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom